Neuland Laboratories (NEULANDLAB.NS) Stock Price

Neuland Laboratories Price

NSE·CLOSED
21,080.00
​
Market closed

Over the last 19 years Neuland Laboratories grew revenue by 12.9% annually, reaching 20.23 B INR. Earnings per share have grown at 17.2% per year over the last 19 years. For Neuland Laboratories, the net margin of 18.0% is up versus 6.9% a few years ago. At today's price the dividend yield works out to roughly 0.06%. The payout ratio is around 7% of earnings. The dividend has grown at 11.0% per year over the past 19 years. The consensus 12-month price target for Neuland Laboratories is 19,023.00 INR, about 9.8% below where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.

Neuland Laboratories stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuland Laboratories business model & stock analysis

Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients.

Frequently asked questions about Neuland Laboratories

Analysts currently set an average price target of 19,756.13 INR for the Neuland Laboratories stock (median: 19,023.00 INR), implying -6.3 % versus the latest price. The consensus is based on 10 analyst ratings.

10 analysts currently rate the Neuland Laboratories stock: 9 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Neuland Laboratories share trades at 205.70 EUR (21,080.00 INR).

The Neuland Laboratories share (NEULANDLAB.NS) is listed on 2 stock exchanges, including: NSE (Indien) (NEULANDLAB.NS).

The revenue of Neuland Laboratories is 20.23 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Neuland Laboratories is 3.64 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Neuland Laboratories is currently 74.30. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Neuland Laboratories stock.

The price-to-sales ratio (P/S) of Neuland Laboratories is currently 13.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Neuland Laboratories stock.

The Eulerpool Quality Score for Neuland Laboratories is 9/10.

The ISIN of Neuland Laboratories is INE794A01010. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Neuland Laboratories is NEULANDLAB.NS. The ticker symbol is used to trade Neuland Laboratories shares on the stock exchange.

Fair ValueTerminal
21,712.40 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
12.86 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
INR
Initial public offering
Apr 18, 1994
ISIN
INE794A01010
Cusip
Y6272R119
Market capitalization
270.46 B INRMega Cap
52-Week Range
PEG
3.36
P/E ratio
P/Ee 2027
62.26
P/Ee 2028
44.94
P/Ee 2029
34.21
P/Se
11.57
EV/EBIT
56.49
P/B Ratio
14.43
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
16.73 %
Dividend
Dividend yield
0.06 %
Est. Dividend Yield
0.16 %
Payout Ratio
6.58 %
Dividend growth Ø5Y
27.73 %
Dividend payments per year
1
Dividend paid since
7 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
20.00 %
Last updated Nov 20, 2026, 3:33 AM

Neuland Laboratories Peer Group

Neuland Laboratories Ticker

BSE · NEULANDLAB.BONSE INDIA · NEULANDLAB.NS

Neuland Laboratories FIGI

NLL:IN · BBG000DWVW81NLL:IB · BBG000DWVWY2NLL:IS · BBG000DWVXK5NLL:IG · BBG003NW0195